Companies operating on both sides of the Atlantic routinely discover that FDA compliance and EMA compliance, while sharing a common scientific foundation, differ in ways that matter operationally. A manufacturing site that passes FDA inspection may fail EMA inspection on the same day. A clinical programme designed to satisfy FDA may need significant supplementation for EMA. Understanding where the systems align and where they diverge is the foundation of an effective transatlantic regulatory strategy.

The Fundamental Difference: Philosophy and Structure

FDA is a single federal agency with unified authority over pharmaceuticals in the USA. EMA is a coordination agency — it coordinates the scientific assessment of medicines through the centralised procedure, but national competent authorities (ANSM, BfArM, MHRA, etc.) retain primary regulatory authority for nationally authorised products and conduct GMP inspections independently.

This structural difference has practical consequences:

FDA inspection: A single FDA inspection covers US market access. Pass it, and you can supply the entire US market.
EU inspection: An EMA inspection (for centrally authorised products) covers EU-wide market access. But for nationally authorised products, the relevant national authority conducts the inspection. A French ANSM inspection covers France; a German BfArM inspection covers Germany. A site supplying multiple EU markets may face multiple national inspections.

GMP: Where FDA and EMA Differ

Both FDA and EMA require GMP compliance, but the specific requirements differ in important areas.

Qualified Person (QP)

The EU requires every manufacturing site to have a Qualified Person (QP) — a named individual with specific educational qualifications and experience who is personally responsible for certifying each batch of medicinal product before it is released for sale. The QP’s certification is a legal act; if a batch is released that doesn’t comply with GMP, the QP bears personal legal liability.

FDA has no direct equivalent to the QP. FDA’s batch release requirements are met through the manufacturer’s quality control system, without a named individual bearing personal legal responsibility.

For non-EU manufacturers supplying the EU market, the QP requirement means either:

Employing a QP at the EU manufacturing site (if the product is manufactured in the EU)
Engaging a contract QP service (for non-EU manufacturers using an EU-based importer or contract manufacturer for batch release)

Process Validation

Both FDA and EMA require process validation, but the approaches differ:

FDA: FDA’s 2011 Process Validation Guidance introduced a lifecycle approach — Stage 1 (process design), Stage 2 (process qualification), Stage 3 (continued process verification). FDA emphasises statistical process control and ongoing monitoring.

EMA: EU GMP Annex 15 on Qualification and Validation requires traditional validation (typically 3 consecutive batches at commercial scale) plus ongoing process verification. The EU approach is more prescriptive about the number of validation batches.

In practice, a validation programme designed to meet EU Annex 15 requirements will generally satisfy FDA requirements, but the reverse is not always true.

Data Integrity

Both FDA and EMA have significantly increased their focus on data integrity in recent years, following a series of high-profile data integrity failures at manufacturing sites in India and China.

FDA: FDA’s data integrity guidance (2018) focuses on ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available). FDA has issued numerous Warning Letters for data integrity violations.

EMA: EMA’s data integrity guidance (2016, updated 2021) is more prescriptive than FDA’s, with specific requirements for audit trails, access controls, and computerised system validation. EU GMP Annex 11 (Computerised Systems) is more detailed than FDA’s 21 CFR Part 11.

Data integrity is consistently the most common finding in both FDA and EMA inspections of manufacturing sites in Asia. Sites preparing for EU inspection should pay particular attention to Annex 11 compliance.

Sterile Manufacturing

EU GMP Annex 1 (Manufacture of Sterile Medicinal Products) was comprehensively revised in 2022 — the first major revision since 2008. The new Annex 1 introduced:

Contamination Control Strategy (CCS): A holistic, risk-based approach to contamination control that must be documented and maintained
Barrier technology: Strong encouragement for RABS (Restricted Access Barrier Systems) and isolators for aseptic processing
Environmental monitoring: More detailed requirements for viable and non-viable particle monitoring
Media fills: Updated requirements for aseptic process simulation

The revised Annex 1 is more demanding than FDA’s aseptic processing guidance (2004) in several areas, particularly around barrier technology and contamination control strategy documentation. Sites manufacturing sterile products for the EU market should review their compliance against the 2022 Annex 1.

Clinical Trials: FDA IND vs EU CTR

FDA IND Process

Under FDA’s Investigational New Drug (IND) application process:

The sponsor submits an IND to FDA before initiating a clinical trial
FDA has 30 days to review the IND and place a clinical hold if there are safety concerns
If FDA does not respond within 30 days, the trial may proceed
IRB (Institutional Review Board) approval is required separately from FDA IND approval

EU CTR Process

Under the EU Clinical Trial Regulation (EU) No 536/2014:

The sponsor submits a single application through CTIS covering all participating member states
The Reporting Member State (RMS) leads the Part I scientific assessment (30-45 days)
Each Concerned Member State (CMS) conducts its own Part II assessment (30 days)
Ethics committee approval is integrated into the Part II assessment (not separate)
Both Part I and Part II must be approved before the trial can start in each member state

Key differences:

EU CTR has no equivalent to the FDA’s 30-day default approval — the trial cannot start until both Part I and Part II are explicitly approved
EU CTR integrates ethics committee review into the regulatory process; FDA separates IRB from IND
EU CTR mandatory result publication has no direct FDA equivalent (though FDA requires ClinicalTrials.gov registration)

Post-Market Obligations: FDA vs EMA

Pharmacovigilance

FDA: Post-market safety reporting under 21 CFR Part 314 (for NDAs) and 21 CFR Part 600 (for biologics). Periodic Safety Reports (PSURs) are not required by FDA — FDA uses Periodic Benefit-Risk Evaluation Reports (PBRERs) for some products.

EMA: Pharmacovigilance is governed by Regulation (EU) No 1235/2010 and Directive 2010/84/EU. Requirements include:

Pharmacovigilance System Master File (PSMF)
Periodic Safety Update Reports (PSURs) — submitted to EMA on a defined schedule
Risk Management Plan (RMP) — required for all new marketing authorisations
Signal detection and management
Post-authorisation safety studies (PASS) where required as a condition of authorisation

The EU pharmacovigilance system is more prescriptive than FDA’s, with more structured reporting requirements and a stronger emphasis on risk management plans.

Variations

FDA: Post-approval changes are managed through Prior Approval Supplements (PAS), Changes Being Effected (CBE-30, CBE-0), and Annual Reports, depending on the significance of the change.

EMA/EU: Post-approval changes are managed through the EU variation system — Type IA (minor, notify within 12 months), Type IB (minor, notify and wait 30 days), Type II (major, full assessment required). The EU variation system is more complex than FDA’s supplement system and requires careful classification of each change.

FDA and EMA compliance are not interchangeable. Companies that assume FDA compliance automatically satisfies EMA requirements — or vice versa — consistently encounter gaps that delay market access or trigger regulatory findings. The most effective transatlantic regulatory strategy is one that identifies the specific differences relevant to your product and manufacturing site, and builds a compliance programme that satisfies both frameworks from the outset.

At Care Europe, we support pharmaceutical companies in developing and implementing transatlantic regulatory strategies, with specific expertise in EU GMP compliance and EMA submission management. Contact us at [email protected].

Pharma Compliance Consulting: FDA vs EMA — Key Differences